Skip to Main Content

NEW YORK — Moderna (MRNA) is gathering investors here Thursday to showcase scientific evidence demonstrating that injections of the company’s custom-built messenger RNA are capable of turning the body’s own cells into medicine-making factories.

The new data being presented from two programs targeting cytomegalovirus (CMV) infection and the mosquito-borne chikungunya virus are preliminary, but they still go further than ever before to prove Moderna’s mRNA technology can create effective drugs and vaccines. However, heart-related side effects seen in a single chikungunya study participant also raise questions about the safety of its mRNA-based medicines.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!